Search

1244447
1240861
1230819
1195994
393884
Final results from M72 AS01E TB Vaccine Trial
The final results from the M72AS01E TB vaccine study have been published in the New England Journal of Medicine. The vaccine demonstrated a 50% efficacy rate in reducing the incidence of lung TB disease in HIV-negative adults, already infected with...
Social Reponsiveness
Established in 2001, the South African Tuberculosis Vaccine Initiative (SATVI) was presented with the University of Cape Town’s (UCT) 2018 Social Responsiveness Award at the Faculty of Health Sciences graduation ceremony on Saturday, 13 April 2019
2018 Tb under the Spotlight Science Engagement
The “TB Under the Spotlight Science Engagement” programme was conceptualised and presented by South African Tuberculosis Vaccine Initiative (SATVI) with scientists from the Division of Molecular Biology and Human Genetics at Stellenbosch University...
Biomarker discovery offers hope for new TB vaccine development
A team of scientists from the University of Cape Town, Oxford University and the London School of Hygiene & Tropical Medicine have made a discovery that reveals how we can improve development of more effective vaccines against tuberculosis.
Community Engagement
Carina's Choice: SATVI collaborated with UCT Drama Department and Worcester Secondary School in developing this play which was performed by learners from Worcester Secondary School at 8 local high schools reaching approximately 8 000 adolescents in...

News

Monday, 27 January 2020
23 October 2019 Vacancy: Laboratory Technologist

SATVI is calling for applicants to the position of Laboratory Technologist at its Worcester field site. NOW CLOSED.

Publication Date:
Thu, 24 Oct 2019 - 11:45
September 2019 Latest research: Plasma Type I IFN Protein Concentrations in Human Tuberculosis

SATVI researchers Professors Mark Hatherill, Tom Scriba, Dr Bilek, Darboe, Mbandi, Penn-Nicholson have co-authored a research article titled "Plasma Type I IFN Protein Concentrations in Human Tuberculosis." appearing in the Frontiers in Cellular and Infection Microbiology.

Publication Date:
Fri, 13 Sep 2019 - 23:00
September 2019 Latest Research Non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis.

Professor Mark Hatherill has co-authored a journal article titled "FDG-PET/CT as a non-invasive biomarker for assessing adequacy of treatment and predicting relapse in patients treated for pulmonary tuberculosis" appearing in the Journal of Nuclear Medicine.

Publication Date:
Fri, 13 Sep 2019 - 22:45
27 August 2019 Vacancy: Postdoctoral Fellowship TB Immunology NOW CLOSED

We are inviting applications for a postdoctoral fellowship in human immunology to conduct research aimed at identifying lung immune signatures of resistance to natural M.tb infection in a multi-cohort study. NOW CLOSED.

Publication Date:
Tue, 27 Aug 2019 - 13:15

Pages